Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood

Dania Vázquez-Blomquist, PhD; Mónica Bequet-Romero, PhD; Yssel Mendoza-Marí, PhD; Gilda Lemos, MSc; Iris Valdés, PhD; Camila Canaán-Haden Ayala; Isabel Gonzáles Moya; Ricardo Martínez Rosales; Giselle Freyre Corrales; Gerardo Guillén-Nieto, PhD

Clinical Immunology Communications (Dec 2022)

Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood

Dania Vázquez-Blomquist, PhD,
Mónica Bequet-Romero, PhD,
Yssel Mendoza-Marí, PhD,
Gilda Lemos, MSc,
Iris Valdés, PhD,
Camila Canaán-Haden Ayala,
Isabel Gonzáles Moya,
Ricardo Martínez Rosales,
Giselle Freyre Corrales,
Gerardo Guillén-Nieto, PhD

Affiliations

Dania Vázquez-Blomquist, PhD: Pharmacogenomic Group, Departament of System Biology, Center for Genetic Engineering and Biotechnology (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana 10600, Cuba; Corresponding author.
Mónica Bequet-Romero, PhD: Pharmaceutic Department, Center for Genetic Engineering and Biotechnology (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana 10600, Cuba
Yssel Mendoza-Marí, PhD: Pharmaceutic Department, Center for Genetic Engineering and Biotechnology (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana 10600, Cuba
Gilda Lemos, MSc: Analytical Lab, Chemistry-Physics Department, Center for Genetic Engineering and Biotechnology (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana 10600, Cuba
Iris Valdés, PhD: Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana 10600, Cuba
Camila Canaán-Haden Ayala: Pharmaceutic Department, Center for Genetic Engineering and Biotechnology (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana 10600, Cuba
Isabel Gonzáles Moya: Pharmaceutic Department, Center for Genetic Engineering and Biotechnology (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana 10600, Cuba
Ricardo Martínez Rosales: Analytical Lab, Chemistry-Physics Department, Center for Genetic Engineering and Biotechnology (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana 10600, Cuba
Giselle Freyre Corrales: Analytical Lab, Chemistry-Physics Department, Center for Genetic Engineering and Biotechnology (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana 10600, Cuba
Gerardo Guillén-Nieto, PhD: Biomedical Research Direction, Center for Genetic Engineering and Biotechnology (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana 10600, Cuba

Journal volume & issue: Vol. 2
pp. 39 – 45

Abstract

Read online

We conducted an experimental protocol with a nasal recombinant IFNα-2b formulation (Nasalferon) in 12 healthy volunteers who received 1 MIU per nostril twice a day, three consecutive days, and studied the induction of biomarkers related to antiviral and immune responses. Nasalferon increases the antiviral biomarker OAS1 transcript levels in oropharynx and PBMCs, regulates molecular and cellular elements related to innate and adaptive immune responses and decreases granulocytes population. These effects support Nasalferon use in virally-exposed populations.

Published in Clinical Immunology Communications

ISSN: 2772-6134 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: https://www.journals.elsevier.com/clinical-immunology-communications

About the journal

Abstract

Keywords